Paul Durrington

Summary

Affiliation: University of Manchester
Country: UK

Publications

  1. ncbi Rosuvastatin and fenofibrate alone and in combination in type 2 diabetes patients with combined hyperlipidaemia
    Paul N Durrington
    University of Manchester, Department of Medicine, Manchester Royal Infirmary, Oxford Road, Manchester M13 9WL, UK
    Diabetes Res Clin Pract 64:137-51. 2004
  2. ncbi HDL in risk prediction and its direct and indirect involvement in atherogenesis
    Paul Durrington
    Department of Medicine, University of Manchester, Oxford Road, Manchester M13 9WL, UK
    Atheroscler Suppl 3:3-12. 2002
  3. ncbi Dyslipidaemia
    Paul Durrington
    University Department of Medicine, Manchester Royal Infirmary, Oxford Road, M13 9WL, Manchester, UK
    Lancet 362:717-31. 2003
  4. ncbi Rosuvastatin: efficacy, safety and clinical effectiveness
    Handrean Soran
    Central Manchester and Manchester Children University Hospital, Department of Endocrinology, Oxford Road, Manchester M13 9WL, UK
    Expert Opin Pharmacother 9:2145-60. 2008
  5. ncbi Paraoxonase 1 activity, concentration and genotype in cardiovascular disease
    Mike Mackness
    University Department of Medicine, Manchester Royal Infirmary, Manchester, UK
    Curr Opin Lipidol 15:399-404. 2004
  6. ncbi Variation in paraoxonase-1 activity and atherosclerosis
    Handrean Soran
    University Department of Medicine, Central Manchester and Manchester Children s University Hospitals Foundation Trust, Manchester, UK
    Curr Opin Lipidol 20:265-74. 2009
  7. ncbi The effect of atorvastatin on serum lipoproteins in acromegaly
    Manoj Mishra
    Cardiovascular, Medicine and Surgery Central Clinical Academic Group, University of Manchester, M13 9PT, UK
    Clin Endocrinol (Oxf) 62:650-5. 2005
  8. ncbi Low paraoxonase activity predicts coronary events in the Caerphilly Prospective Study
    Bharti Mackness
    University Department of Medicine, Manchester Royal Infirmary, University of Manchester, Oxford Rd, Manchester M13 9WL, UK
    Circulation 107:2775-9. 2003
  9. ncbi Clinical management of children and young adults with heterozygous familial hypercholesterolaemia in the UK
    Owen Greene
    University Department of Medicine, Manchester Royal Infirmary, Oxford Road, Manchester M13 9WL, UK
    J R Soc Med 97:226-9. 2004
  10. ncbi Cord blood lipoproteins and prenatal influences
    Narinder Bansal
    Clinical Epidemiology and Cardiovascular Medicine Group, Division of Cardiovascular and Endocrine Science, University Department of Medicine, Manchester Royal Infirmary, UK
    Curr Opin Lipidol 16:400-8. 2005

Collaborators

Detail Information

Publications38

  1. ncbi Rosuvastatin and fenofibrate alone and in combination in type 2 diabetes patients with combined hyperlipidaemia
    Paul N Durrington
    University of Manchester, Department of Medicine, Manchester Royal Infirmary, Oxford Road, Manchester M13 9WL, UK
    Diabetes Res Clin Pract 64:137-51. 2004
    ....
  2. ncbi HDL in risk prediction and its direct and indirect involvement in atherogenesis
    Paul Durrington
    Department of Medicine, University of Manchester, Oxford Road, Manchester M13 9WL, UK
    Atheroscler Suppl 3:3-12. 2002
  3. ncbi Dyslipidaemia
    Paul Durrington
    University Department of Medicine, Manchester Royal Infirmary, Oxford Road, M13 9WL, Manchester, UK
    Lancet 362:717-31. 2003
    ..Lipid disorders are mainly straightforward, but some are complex or resistant to simple treatment strategies. I have reviewed the clinical manifestations of disordered lipid metabolism (dyslipidaemia) and its management...
  4. ncbi Rosuvastatin: efficacy, safety and clinical effectiveness
    Handrean Soran
    Central Manchester and Manchester Children University Hospital, Department of Endocrinology, Oxford Road, Manchester M13 9WL, UK
    Expert Opin Pharmacother 9:2145-60. 2008
    ..Rosuvastatin is a fully synthetic statin developed by AstraZeneca. It is a competitive inhibitor of 3-hydroxy-3-methyl-glutaryl-CoA reductase...
  5. ncbi Paraoxonase 1 activity, concentration and genotype in cardiovascular disease
    Mike Mackness
    University Department of Medicine, Manchester Royal Infirmary, Manchester, UK
    Curr Opin Lipidol 15:399-404. 2004
    ..To provide up-to-date information on the most recent advances in the epidemiology, biochemistry and molecular biology of the antiatherosclerotic enzyme paraoxonase 1...
  6. ncbi Variation in paraoxonase-1 activity and atherosclerosis
    Handrean Soran
    University Department of Medicine, Central Manchester and Manchester Children s University Hospitals Foundation Trust, Manchester, UK
    Curr Opin Lipidol 20:265-74. 2009
    ..Finally, evidence that pharmacological agents may affect PON1 activity is summarized...
  7. ncbi The effect of atorvastatin on serum lipoproteins in acromegaly
    Manoj Mishra
    Cardiovascular, Medicine and Surgery Central Clinical Academic Group, University of Manchester, M13 9PT, UK
    Clin Endocrinol (Oxf) 62:650-5. 2005
    ..CONCLUSION: Atorvastatin treatment was safe, well tolerated and effective in improving the atherogenic lipoprotein profile in acromegaly...
  8. ncbi Low paraoxonase activity predicts coronary events in the Caerphilly Prospective Study
    Bharti Mackness
    University Department of Medicine, Manchester Royal Infirmary, University of Manchester, Oxford Rd, Manchester M13 9WL, UK
    Circulation 107:2775-9. 2003
    ..The hypothesis that paraoxonase (PON1) has a role in preventing atherosclerosis is based on experimental, transgenic, and case-control studies but has not previously been tested prospectively...
  9. ncbi Clinical management of children and young adults with heterozygous familial hypercholesterolaemia in the UK
    Owen Greene
    University Department of Medicine, Manchester Royal Infirmary, Oxford Road, Manchester M13 9WL, UK
    J R Soc Med 97:226-9. 2004
    ..Despite the efficacy of statins in reducing low-density-lipoprotein cholesterol, these agents are little used in children with FH. Their safety and clinical efficacy should be assessed by a randomized double-blind trial...
  10. ncbi Cord blood lipoproteins and prenatal influences
    Narinder Bansal
    Clinical Epidemiology and Cardiovascular Medicine Group, Division of Cardiovascular and Endocrine Science, University Department of Medicine, Manchester Royal Infirmary, UK
    Curr Opin Lipidol 16:400-8. 2005
    ..Genetic and environmental influences affect cord blood lipoproteins, but how this occurs and the relative contribution of these influences to the overall profile in healthy newborns remains uncertain...
  11. ncbi Effects of hormone replacement therapy on insulin-like growth factor (IGF)-I, IGF-II and IGF binding protein (IGFBP)-1 to IGFBP-4: implications for cardiovascular risk
    Adrian Heald
    Department of Diabetes and Endocrinology, University of Manchester, Salford Royal Hospitals University Trust, Salford, UK
    Gynecol Endocrinol 20:176-82. 2005
    ....
  12. ncbi Effects of dydrogesterone and norethisterone, in combination with oestradiol, on lipoproteins and inflammatory markers in postmenopausal women
    See Kwok
    Barlow Medical Centre, 8 Barlow Moor Road, Manchester M20 6TR, UK
    Maturitas 53:439-46. 2006
    ....
  13. ncbi Analysis of efficacy and safety in patients aged 65-75 years at randomization: Collaborative Atorvastatin Diabetes Study (CARDS)
    H Andrew W Neil
    Division of Public Health and Primary Health Care, University of Oxford, Old Road Campus, Headington, Oxford OX3 7LF, UK
    Diabetes Care 29:2378-84. 2006
    ..We conducted a post hoc analysis to compare the efficacy and safety of atorvastatin among 1,129 patients aged 65-75 years at randomization with 1,709 younger patients in the Collaborative Atorvastatin Diabetes Study (CARDS)...
  14. ncbi European guidelines on cardiovascular disease prevention in clinical practice: executive summary
    Ian Graham
    Department of Cardiology, The Adelaide and Meath Hospital, Dublin, Ireland
    Eur Heart J 28:2375-414. 2007
  15. ncbi Hypercholesterolaemia and its management
    Deepak Bhatnagar
    University of Manchester Cardiovascular Research Group, Core Technology Facility, Manchester M13 9NT
    BMJ 337:a993. 2008
  16. ncbi European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by r
    Ian Graham
    Department of Cardiology, The Adelaide and Meath Hospital, Tallaght, Doublin, Ireland
    Eur J Cardiovasc Prev Rehabil 14:E1-40. 2007
  17. ncbi European guidelines on cardiovascular disease prevention in clinical practice: full text. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by represent
    Ian Graham
    Department of Cardiology, The Adelaide and Meath Hospital, Tallaght, Dublin, Ireland
    Eur J Cardiovasc Prev Rehabil 14:S1-113. 2007
  18. ncbi [European practice guidelines on prevention of cardiovascular diseases: executive summary]
    Ian Graham
    European Society of Cardiology
    G Ital Cardiol (Rome) 9:11-59. 2008
  19. ncbi Nonesterified fatty acids as mediators of glucose intolerance in Indian Asian populations
    Jeetesh V Patel
    University Dept. of Medicine, Manchester Royal Infirmary, Manchester M13 9WL, U.K
    Diabetes Care 28:1505-7. 2005
  20. ncbi Progestogens of varying androgenicity and cardiovascular risk factors in postmenopausal women receiving oestrogen replacement therapy
    See Kwok
    Barlow Medical Center, Manchester, UK
    Clin Endocrinol (Oxf) 61:760-7. 2004
    ....
  21. ncbi Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial
    Helen M Colhoun
    EURODIAB, Department of Epidemiology and Public Health, Royal Free and University College Medical School, London, UK
    Lancet 364:685-96. 2004
    ..We aimed to assess the effectiveness of atorvastatin 10 mg daily for primary prevention of major cardiovascular events in patients with type 2 diabetes without high concentrations of LDL-cholesterol...
  22. ncbi Paraoxonase activity and genetic polymorphisms in greenhouse workers with long term pesticide exposure
    Antonio F Hernandez
    Department of Legal Medicine and Toxicology, University of Granada School of Medicine, Spain
    Hum Exp Toxicol 22:565-74. 2003
    ..This study suggests that chronic exposure to pesticides might decrease PON1 activity and pinpoints the potential usefulness of monitoring PON1 activity in occupational settings where exposure to organophosphates occurs...
  23. ncbi Alstrom syndrome (OMIM 203800): a case report and literature review
    Tisha Joy
    Department of Vascular Biology and Medicine, Robarts Research Institute and Schulich School of Medicine and Dentistry, University of Western Ontario, London, Ontario, Canada
    Orphanet J Rare Dis 2:49. 2007
    ..Mutations in the ALMS1 gene have been found to be causative for AS with a total of 79 disease-causing mutations having been described...
  24. ncbi Measurement of plasma small-dense LDL concentration by a simplified ultracentrifugation procedure and immunoassay of apolipoprotein B
    Valentine C Menys
    Department of Medicine, Manchester Royal Infirmary, Oxford Road, M13 9WL, Manchester, UK
    Clin Chim Acta 334:95-106. 2003
    ..Existing methods for detecting small-dense low-density lipoprotein (SD-LDL) are either semiquantitative (e.g., gradient gel electrophoresis) or require specialised laboratory methods (e.g., density-gradient ultracentrifugation, DGU)...
  25. ncbi Patients' understandings and experiences of familial hypercholesterolemia
    Kate Weiner
    Institute for Science and Society, University of Nottingham, Nottingham, UK
    Community Genet 11:273-82. 2008
    ..To explore patients' understanding and experiences of familial hypercholesterolemia (FH) and the significance of the hereditary aspect of the condition...
  26. ncbi Paraoxonase and coronary heart disease
    Michael I Mackness
    University Department of Medicine, Manchester Royal Infirmary, Oxford Road, Manchester M13 9WL, UK
    Atheroscler Suppl 3:49-55. 2002
    ..PON1 is extensively researched and strategies will hopefully emerge to increase its activity and provide a more satisfactory test of the antioxidant hypothesis of atherosclerosis than antioxidant vitamins have done...
  27. ncbi The paraoxonase gene family and coronary heart disease
    Bharti Mackness
    University Department of Medicine, Manchester Royal Infirmary, UK
    Curr Opin Lipidol 13:357-62. 2002
    ..Significant advances have been made in understanding the basic biochemical function of paraoxonase 1 and the discovery of possible modulators of its activity...
  28. ncbi The safety and tolerability of atorvastatin 10 mg in the Collaborative Atorvastatin Diabetes Study (CARDS)
    Connie B Newman
    Department of Medicine, New York University School of Medicine, VA Hospital, 423 East 23rd Street, Dept of Medicine 11093 South, New York, NY 10010, USA
    Diab Vasc Dis Res 5:177-83. 2008
    ..Overall, these data demonstrate that atorvastatin 10 mg was well tolerated in patients with type 2 diabetes during long-term treatment...
  29. ncbi Isolation of plasma small-dense low-density lipoprotein using a simple air-driven ultracentrifuge and quantification using immunoassay of apolipoprotein B
    Valentine C Menys
    Department of Medicine, Manchester Royal Infirmary, Oxford Road, Manchester M13 9WL, UK
    Clin Chem Lab Med 42:30-6. 2004
    ..237; p < 0.05) and dyslipidaemic men (r = -0.293; p < 0.005). Using a micro-method, we obtained results which establish that the Airfuge provides a more rapid and less expensive method for quantification of SD-LDL...
  30. ncbi Systemic lupus erythematosus: an independent risk factor for endothelial dysfunction in women
    Masoud El-Magadmi
    University of Manchester arc Epidemiology Unit, Manchester Royal Infirmary, Central Manchester and Manchester Children's University Hospitals NHS Trust, Manchester, UK
    Circulation 110:399-404. 2004
    ..Understanding the mechanism(s) of endothelial dysfunction in SLE may suggest novel strategies for CHD prevention in this context...
  31. ncbi Molecular characterization of two patients with severe LCAT deficiency
    Valentine Charlton-Menys
    Cardiovascular Research Group, University of Manchester, Manchester Royal Infirmary, Manchester, UK
    Nephrol Dial Transplant 22:2379-82. 2007
  32. ncbi Squalene synthase inhibitors : clinical pharmacology and cholesterol-lowering potential
    Valentine Charlton-Menys
    Division of Cardiovascular and Endocrine Sciences, Cardiovascular Research Group, Core Technology Facility, University of Manchester, Manchester, UK
    Drugs 67:11-6. 2007
    ..Squalene synthase inhibitors are just now entering clinical trials and data on how effectively they lower LDL-cholesterol and how they compliment the actions of statins and other agents is awaited with considerable interest...
  33. ncbi The role of paraoxonase 1 activity in cardiovascular disease: potential for therapeutic intervention
    Michael I Mackness
    University Department of Medicine, Manchester Royal Infirmary, Manchester, UK
    Am J Cardiovasc Drugs 4:211-7. 2004
    ....
  34. ncbi Risks and benefits of omega 3 fats for mortality, cardiovascular disease, and cancer: systematic review
    Lee Hooper
    School of Medicine, Health Policy and Practice, University of East Anglia, Norwich NR4 7TJ
    BMJ 332:752-60. 2006
    ..To review systematically the evidence for an effect of long chain and shorter chain omega 3 fatty acids on total mortality, cardiovascular events, and cancer...
  35. ncbi Adiponectin in umbilical cord blood is inversely related to low-density lipoprotein cholesterol but not ethnicity
    Narinder Bansal
    Clinical Epidemiology Group, University of Manchester Medical School, Stopford Building, Oxford Road, Manchester, United Kingdom
    J Clin Endocrinol Metab 91:2244-9. 2006
    ..Because ethnic disparities in cardiovascular risk have been attributed to low adiponectin and its associated low high-density lipoprotein cholesterol (HDL-C), investigation at birth may help determine the etiology of these risk patterns...
  36. ncbi Hyperinsulinemia, insulin resistance, and circulating oxidized low density lipoprotein in women with systemic lupus erythematosus
    Masoud El Magadmi
    ARC Epidemiology Unit, Rheumatism Research Centre, University of Manchester, UK
    J Rheumatol 33:50-6. 2006
    ..Insulin resistance may therefore represent an additional CHD risk factor in patients with SLE...
  37. ncbi Apolipoprotein A5 and hypertriglyceridemia
    Valentine Charlton-Menys
    Clin Chem 51:295-7. 2005
  38. ncbi Analysis of predicted coronary heart disease risk in England based on Framingham study risk appraisal models published in 1991 and 2000
    Kiran Nanchahal
    Health Promotion Research Unit, Department of Public Health and Policy, London School of Hygiene and Tropical Medicine, London WC1E 7HT
    BMJ 325:194-5. 2002